The limitations of current chemotherapeutic drugs are still a major issue in cancer treatment.
Thus, targeted multimodal therapeutic approaches need to be strategically developed to …

Diclofenac (DCF) is a well-known and widely used non-steroidal anti-inflammatory drug
(NSAID), with a range of actions which are of interest in an oncological context. While there …

A series of diclofenac N-derivatives (2, 4, 6, 8c, 9c, 10a-c) were synthesized in order to test
their anti-cancer and anti-inflammatory effects. The anticarcinogen activity has been …

Combining NSAIDs with conventional therapeutics was recently explored as a new strategy
in cancer therapy. Our earlier studies showed that novel oleanolic acid oximes (OAO) …

Sorafenib is the first developed systemic treatment for advanced forms of hepatocellular
carcinoma, which constitutes the most frequent form of primary liver cancers and is a major …

We investigate the emission from confined excitons in the structure of a single-monolayer-
thick quasi-two-dimensional (quasi-2D) InxGa1− xN layer inserted in GaN matrix. This quasi …

Diclofenac is one of the most prescribed non-steroidal anti-inflammatory drugs (NSAIDs) for
acute and chronic inflammatory conditions. Taking into consideration the extensive use of …

Objective: To investigate the potential synergistic activity of diclofenac with piperine and D-
limonene in inducing apoptosis and cell cycle arrest in breast cancer MCF-7 cells. Methods …

Hepatocellular carcinoma (HCC) is one of the most common tumor types, and is the third
leading cause of cancer mortalities worldwide. A large number of patients with HCC are …

The aim of this study was to analyze dihydrolipoyllysine-residue acetyltransferase (DLAT)
expression and diagnostic ability in hepatocellular carcinoma (HCC), assess its role in HCC …